Huperzine A is an alkaloid isolated from the Chinese club moss Huperzia serrata. It blocks acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine, which puts it in the same drug class as the Alzheimer’s medicines donepezil, rivastigmine and galantamine. In China it has been used as a medicine for Alzheimer’s disease; in the US it is sold as an ingredient in over-the-counter memory and “pre-workout” supplements.
The single most important fact is that the best-run trial outside China was negative. In the US phase 2 trial run by the Alzheimer’s Disease Cooperative Study, the dose the investigators described as effective in China (200 µg twice daily) had no effect on its primary cognitive outcome at 16 weeks (Rafii et al., Neurology 2011). The positive meta-analyses rest mostly on small Chinese trials with a high risk of bias, and there is no good evidence that it improves memory or focus in healthy adults.
This page summarizes what the clinical trials, systematic reviews and pharmacology studies report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Class | Plant alkaloid; reversible, selective acetylcholinesterase (AChE) inhibitor |
| Other names | HupA; Huperzia serrata extract (supplements may list the plant rather than the pure compound) |
| Formula | C₁₅H₁₈N₂O, 242.32 g/mol (PubChem CID 854026) |
| Route | Oral (tablets or capsules in the trials cited here) |
| Studied doses | 200–800 µg/day in Alzheimer’s trials (average ≈370 µg/day across 20 trials); 200 or 400 µg twice daily in the US phase 2 trial |
| Half-life | ≈12 h in healthy young adults (two studies); an early 6-person study with only 10 h of sampling reported ≈4.8 h |
| Effect on blood enzymes | Inhibits red-cell AChE by 30–40% at 100 µg and over 50% at 400 µg; plasma butyrylcholinesterase is not affected |
| US status | Sold in dietary supplements; the FDA does not review supplements for safety or effectiveness before sale |
| WADA status | Not named on the 2026 Prohibited List |
What it is
Investigators in China identified huperzine A as a potent acetylcholinesterase inhibitor in the 1980s (Rafii et al., Neurology 2011). Its chemical name is (1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.0²,⁷]trideca-2(7),3,10-trien-5-one (PubChem). Supplements may contain the purified compound or a plant extract standardized to a stated huperzine A content.
Mechanism
Acetylcholine is a chemical messenger used by nerve cells involved in memory and attention, and also by the nerves that control the gut, heart rate, bladder, airways and muscles. Acetylcholinesterase normally clears it from the synapse very quickly. By blocking that enzyme, huperzine A lets acetylcholine build up at the synapse, which is the same strategy used by the approved Alzheimer’s drugs.
Key properties reported in a review by researchers at the Shanghai Institute of Materia Medica (Wang et al., Acta Pharmacol Sin 2006):
- Reversible and highly specific for AChE. It binds the enzyme but lets go again, unlike the organophosphate pesticides and nerve agents that inactivate it permanently.
- Brain penetration. It crosses the blood-brain barrier, and in the authors’ comparison it has a longer duration of AChE inhibition than tacrine, donepezil and rivastigmine.
- Other effects in the laboratory. In cell culture and animal studies, huperzine A blocked NMDA-type glutamate receptors and protected nerve cells against several kinds of injury. These findings have not been shown to matter in people.
In 12 healthy older volunteers given rising doses, huperzine A inhibited red-blood-cell AChE by 30–40% at 100 µg and by more than 50% at 400 µg, with a peak about 1.5 h after the dose. Plasma butyrylcholinesterase, the second enzyme that breaks down acetylcholine, was not affected (Haigh et al., Chem Biol Interact 2008). Because it occupies AChE reversibly, the US Army has studied it as a pretreatment against nerve agents, which is why some of the human data come from military research.
Pharmacokinetics
Huperzine A is absorbed quickly after an oral dose and has a half-life of roughly half a day in young adults:
| Study | Subjects | Dose | Peak level | Time to peak | Elimination half-life |
|---|---|---|---|---|---|
| Qian et al., 1995 | 6 healthy adults | 0.99 mg tablet | 8.4 µg/L | 79.6 min | 288.5 min (≈4.8 h) |
| Li et al., 2007 | 12 healthy adults aged 20–25 | 0.4 mg tablet | 2.59 ng/mL | 58 min | 716 min (≈11.9 h) |
| Wu et al., 2017 | Healthy Chinese men, 3 formulations | Single dose (reference tablet) | 1.55 ng/mL | not stated in abstract | 12.1 h |
The 1995 study drew blood only up to 10 h after the dose. The two later studies, with sampling to 72 h in the 2017 study, both reported an elimination half-life of about 12 h. The 2007 study found that the drug appeared in plasma within 5–10 minutes and was distributed rapidly before a slower elimination phase.
Age matters. A population model built from 49 elderly Chinese subjects (14 healthy volunteers and 35 Alzheimer’s patients) found that age was the main factor affecting clearance, which falls as age rises in the model (Sheng et al., Acta Pharmacol Sin 2016). The authors note that huperzine A behaves differently in elderly and young subjects, so the 12 h figure from young volunteers should not be assumed for older adults.
The enzyme effect also outlasts the peak blood level. In the healthy older volunteers above, red-cell AChE activity was still about 10% below baseline 48 h after the last 400 µg dose (Haigh et al., 2008).
Regulatory status
- China. Huperzine A is used to treat Alzheimer’s disease patients in China (Sheng et al., 2016), and Chinese phase 4 trials have been reported (Wang et al., 2006).
- United States. It is one of the common ingredients in over-the-counter memory supplements sold in pharmacies and grocery stores. The FDA does not have authority to approve dietary supplements’ safety, effectiveness or labeling before they are sold (Hersant et al., CNS Drugs 2023).
- Sport. Huperzine A is not named on the WADA 2026 Prohibited List.
What the research shows
Alzheimer’s disease: the US phase 2 trial
The largest trial run outside China randomized 210 people with mild to moderate Alzheimer’s disease to placebo, huperzine A 200 µg twice daily or 400 µg twice daily for at least 16 weeks; 177 completed the treatment phase (Rafii et al., Neurology 2011). The primary analysis compared the 200 µg twice-daily dose, described by the authors as the dose shown to be effective in China, against placebo on the ADAS-Cog, a standard cognitive scale used in Alzheimer’s drug trials.
| Comparison | Result |
|---|---|
| 200 µg twice daily vs placebo, ADAS-Cog at week 16 (primary outcome) | −0.32 vs −0.34 points; p = 0.98 (no effect) |
| 400 µg twice daily vs placebo, ADAS-Cog at week 11 (secondary) | 2.27-point improvement vs 0.29-point decline; p = 0.001 |
| 400 µg twice daily vs placebo, ADAS-Cog at week 16 (secondary) | 1.92-point vs 0.34-point improvement; p = 0.07 |
| Global impression, daily activities, behavior (NPI) | Not significant at either dose |
The authors concluded that the primary analysis showed no cognitive benefit at 200 µg twice daily. The 400 µg signal came from secondary analyses and was not significant at the trial’s 16-week endpoint, so it remains a hypothesis that would need its own trial. The study was rated Class III evidence.
Alzheimer’s disease: systematic reviews of the Chinese trials
Most of the trial evidence comes from China, and the reviews that pool it reach positive but heavily qualified conclusions:
| Review | Trials included | Main finding | Quality caveat |
|---|---|---|---|
| Cochrane, Li et al. 2008 | 6 RCTs, 454 patients | MMSE +2.81 points vs placebo (95% CI 1.87–3.76); benefits on ADAS-Cog, global status and daily living; no benefit on the Hasegawa scale or Wechsler Memory Scale | Only one trial was of adequate quality and size; “inadequate evidence to make any recommendation” |
| Yang et al., PLoS One 2013 | 20 RCTs, 1,823 patients | MMSE, daily living and some memory scales favored huperzine A at 8–16 weeks | Most trials at high risk of bias; findings “should be interpreted with caution” |
| Ghassab-Abdollahi et al., Phytother Res 2021 | Overview of 6 systematic reviews | Possible benefit on cognition and daily living in Alzheimer’s | Insufficient evidence because of high heterogeneity and low-quality primary studies |
The Cochrane search was run in February 2006, so it predates the US phase 2 trial. The MMSE (Mini-Mental State Examination) is a short cognitive screening test on which higher scores are better.
Why the Chinese trials carry limited weight
The 2013 review laid out the problems in detail (Yang et al., PLoS One 2013):
- Where and how they were reported. All 20 trials except one were conducted in China, and 18 were published only in Chinese. The one US trial, Rafii 2011, was the only trial at low risk of selective outcome reporting.
- Randomization and concealment. 15 of 20 trials (75%) only said they were “randomized” without describing the method, and 19 of 20 (95%) gave no information on allocation concealment.
- Blinding. Only 7 of 20 trials were double-blind; 9 gave no information on blinding.
- Missing data. Most trials did not report dropouts, so an intention-to-treat analysis was not possible.
- Short duration. Treatment lasted 8–36 weeks, averaging 14.7 weeks, which can show only short-term symptom change.
- Possible publication bias. Funnel plots were asymmetrical, and because nearly every trial claimed a positive effect, the authors suspected negative studies went unpublished.
One of the better-described Chinese trials randomized 202 patients at 15 centers to 400 µg/day or placebo for 12 weeks. It reported that 56.1% of the huperzine A group vs 12.5% of the placebo group improved by 4 or more ADAS-Cog points (Zhang et al., Zhonghua Yi Xue Za Zhi 2002). That size of effect is much larger than anything seen in the US trial with the same daily dose.
Vascular dementia and mild cognitive impairment
- Vascular dementia. A Cochrane review found only one eligible placebo-controlled trial, with 14 participants. It showed no significant effect on the MMSE (+2.40 points; 95% CI −4.78 to 9.58), and the authors found no convincing evidence of value (Hao et al., Cochrane 2009).
- Mild cognitive impairment. A Cochrane review searched English and Chinese databases and found no eligible randomized placebo-controlled trials at all (Yue et al., Cochrane 2012).
Traumatic brain injury
A US phase 2 placebo-controlled pilot trial gave huperzine A or placebo for 12 weeks to people with moderate to severe traumatic brain injury. It was stopped early after enrolling 14 of a planned 30 participants (NCT01676311). Memory scores did not differ between the groups, while the placebo group improved significantly on learning and memory, which the authors attributed to a placebo effect (Zafonte et al., Brain Inj 2020).
Healthy adults and “nootropic” use
There is no good evidence that huperzine A improves memory, focus or exercise performance in healthy adults. The two controlled studies found are small and point in opposite directions:
| Study | Who | Design and dose | Result |
|---|---|---|---|
| Sun et al., 1999 | 34 matched pairs of Chinese middle-school students who complained of poor memory | Double-blind, matched pairs; 100 µg twice daily for 4 weeks | Memory quotient 115 vs 104 on placebo (p under 0.01) |
| Wessinger et al., 2021 | 15 exercise-trained adults | Randomized double-blind crossover; single 200 µg dose | No difference in any cognitive test (digit span, verbal fluency, Stroop), balance, dart throwing, strength or aerobic tests; exercise rated harder after huperzine A (6.8 vs 5.7 on a 0–10 scale; p = 0.002) |
The 1999 study is a single, small, 4-week trial in adolescents who were selected for memory complaints, published in a Chinese journal with no replication. The 2021 trial is the only test of the pre-workout use case, and its authors concluded that huperzine A’s inclusion in pre-workout products “warrants reconsideration.” A 2023 review of over-the-counter memory supplements classed the evidence for huperzine A as mixed (Hersant et al., CNS Drugs 2023).
Side effects and risks
Cholinergic side effects
Because huperzine A raises acetylcholine throughout the body, its side effects are the same kind seen with prescription cholinesterase inhibitors. Across the 20 Alzheimer’s trials in the 2013 review, the adverse events reported were mild (Yang et al., 2013). The number of trials reporting each event was:
| Adverse event | Trials reporting it (of 20) |
|---|---|
| Nausea | 7 |
| Loss of appetite | 5 |
| Dizziness | 4 |
| Vomiting | 4 |
| Constipation | 3 |
| Insomnia | 3 |
| Abdominal pain | 2 |
| Diarrhea, sleepiness, hyperactivity, nasal congestion, edema | 1 each |
Seven of the 20 trials did not report adverse events at all, so the review authors said firm conclusions about safety cannot be drawn. In the US phase 2 trial, serious adverse events occurred in 8.2% on placebo, 13.0% on 200 µg twice daily and 16.2% on 400 µg twice daily. These differences were not statistically significant, and none of the events was judged related to the drug (Rafii et al., 2011). Dropouts were 9, 10 and 14 in the three arms.
Class warnings for cholinesterase inhibitors
Huperzine A has no FDA label. The labeled warnings for donepezil describe risks that follow from the shared mechanism (Aricept label, DailyMed). They have not been studied specifically for huperzine A, but apply to the class:
- Slow heart rate. Cholinesterase inhibitors can slow the heart’s natural pacemaker and conduction, causing bradycardia or heart block, even in people without known conduction problems. Fainting has been reported with donepezil.
- Stomach ulcers and bleeding. More acetylcholine increases stomach acid, which matters most for people with a history of ulcers or those taking NSAIDs.
- Nausea, vomiting and diarrhea. These are dose-related.
- Bladder outflow obstruction.
- Seizures. Cholinomimetics are believed to have some potential to cause generalized seizures.
- Asthma and COPD. The label advises care in people with asthma or obstructive lung disease.
- Anesthesia. They are likely to exaggerate the muscle relaxation from succinylcholine-type drugs used during surgery.
Interactions with other cholinergic drugs and supplements
The donepezil label lists two mechanism-based interactions for the class (Aricept label):
- Additive effects with other cholinesterase inhibitors, with succinylcholine and similar neuromuscular blockers, and with cholinergic agonists such as bethanechol.
- Opposing effects with anticholinergic medicines, such as many bladder, allergy and older antidepressant drugs.
The US phase 2 trial excluded anyone who had taken a cholinesterase inhibitor or a medicine with strong central anticholinergic activity within 2 months, so the trial data do not describe combined use (Rafii et al., 2011). Taking huperzine A alongside a prescribed donepezil, rivastigmine or galantamine would stack two drugs with the same action.
Huperzine A is often sold together with choline sources such as citicoline and Alpha-GPC. No controlled study of these combinations was found, so neither added benefit nor added harm has been measured. The combination is not a substitute for medical review in anyone taking prescription cholinergic or anticholinergic drugs.
Who should be cautious
Based on the class warnings above, the groups at greatest risk are people with:
- slow heart rate or heart conduction disease;
- active or past stomach ulcers, or regular NSAID use;
- asthma or chronic obstructive lung disease;
- epilepsy;
- urinary retention;
- upcoming surgery under general anesthesia;
- current use of a prescription cholinesterase inhibitor or anticholinergic drug.
No pregnancy or breastfeeding safety data were found for huperzine A.
Key takeaways
- A real acetylcholinesterase inhibitor. Huperzine A blocks the same enzyme as donepezil and measurably inhibits it in human blood, with a half-life of about 12 h in young adults.
- The best US trial was negative. At 200 µg twice daily, the dose reported effective in China, it did not improve the primary cognitive outcome in 210 people with Alzheimer’s disease; a 400 µg signal was secondary only.
- Positive reviews rest on weak trials. Cochrane and later reviews found benefits on paper, but 19 of 20 trials were Chinese and most were at high risk of bias, with signs of publication bias.
- No good evidence in healthy adults. One small 1999 study in students was positive; the only pre-workout trial found no cognitive or performance benefit.
- Cholinergic side effects and interactions. Nausea, dizziness and appetite loss were the most reported effects; class risks include slow heart rate and ulcers, with additive effects alongside other cholinergic drugs.
Sources
- Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27(1):1–26. PubMed.
- National Center for Biotechnology Information. Huperzine A, PubChem CID 854026. PubChem.
- Qian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Zhongguo Yao Li Xue Bao. 1995;16(5):396–398. PubMed.
- Li YX, Zhang RQ, Li CR, Jiang XH. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet. 2007;32(4):183–187. PubMed.
- Wu SL, Gan J, Rao J, et al. Pharmacokinetics and tolerability of oral dosage forms of huperzine a in healthy Chinese male volunteers: a randomized, single dose, three-period, six-sequence crossover study. J Huazhong Univ Sci Technolog Med Sci. 2017;37(5):795–802. PubMed.
- Sheng L, Qu Y, Yan J, et al. Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016;37(7):994–1001. PubMed.
- Haigh JR, Johnston SR, Peppernay A, et al. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 2008;175(1-3):380–386. PubMed.
- Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–1394. PubMed; PMC.
- Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev. 2008;(2):CD005592. PubMed.
- Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(9):e74916. PubMed; PMC.
- Ghassab-Abdollahi N, Mobasseri K, Dehghani Ahmadabad A, et al. The effects of Huperzine A on dementia and mild cognitive impairment: an overview of systematic reviews. Phytother Res. 2021;35(9):4971–4987. PubMed.
- Zhang Z, Wang X, Chen Q, et al. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial [in Chinese]. Zhonghua Yi Xue Za Zhi. 2002;82(14):941–944. PubMed.
- Hao Z, Liu M, Liu Z, Lv D. Huperzine A for vascular dementia. Cochrane Database Syst Rev. 2009;(2):CD007365. PubMed.
- Yue J, Dong BR, Lin X, et al. Huperzine A for mild cognitive impairment. Cochrane Database Syst Rev. 2012;12:CD008827. PubMed.
- Zafonte RD, Fregni F, Bergin MJG, et al. Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect. Brain Inj. 2020;34(1):34–41. PubMed.
- Spaulding Rehabilitation Hospital. Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI. ClinicalTrials.gov NCT01676311. ClinicalTrials.gov.
- Sun QQ, Xu SS, Pan JL, Guo HM, Cao WQ. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Zhongguo Yao Li Xue Bao. 1999;20(7):601–603. PubMed.
- Wessinger CM, Inman CL, Weinstock J, Weiss EP. Effect of Huperzine A on cognitive function and perception of effort during exercise: a randomized double-blind crossover trial. Int J Exerc Sci. 2021;14(2):727–741. PubMed.
- Hersant H, He S, Maliha P, Grossberg G. Over the counter supplements for memory: a review of available evidence. CNS Drugs. 2023;37(9):797–817. PubMed.
- Eisai Inc. Aricept (donepezil hydrochloride) tablets, prescribing information. DailyMed.
- World Anti-Doping Agency. The 2026 Prohibited List. WADA.